Market Insights Snapshot
Remedi, a renowned cannabis brand, has demonstrated a steady performance across various categories in the state of Illinois. In the Capsules category, the brand has consistently stayed within the top 6 rankings from August to November 2023, even improving its rank to 5th in October. Similarly, in the Tincture & Sublingual category, Remedi has held a strong position in the top 4, even advancing to 3rd in November. While the brand has seen a slight fluctuation in the Concentrates category, with ranks varying from 16th to 20th, it has managed to maintain its presence in the top 20.
However, the scenario is quite different in the state of Massachusetts, where Remedi's performance in the Concentrates category has seen a significant decline. The brand, which was ranked 45th in August 2023, slipped to 80th by November. This indicates that Remedi was not able to secure a position in the top 20 brands for this category in this state. It's important to note that rankings are indicative of the brand's popularity and sales performance, and a drop in rankings might suggest a need for strategy reassessment in that particular market.
In the Concentrates category within the Illinois market, Remedi has been experiencing a fluctuating rank over the past few months, indicating a dynamic and competitive landscape. In August 2023, Remedi held the 17th rank, which slightly improved to 16th in September, dropped to 20th in October, and then rebounded to 17th in November. This shows a slight downward trend in rank overall. In comparison, FloraCal Farms has seen an improvement in rank, moving from 18th to 16th over the same period. Ozone initially improved, moving from 13th to 11th, but then dropped significantly to 18th rank in November. Avexia has maintained a stable yet lower rank, oscillating between 19th and 20th, while nuEra has consistently ranked higher than Remedi, fluctuating between 15th and 17th. These shifts in ranking indicate a highly competitive market where brands are continuously vying for a better position.
In November 2023, Remedi's top-performing products were led by the Indica Rest RSO Dropper (0.5g) from the Concentrates category, maintaining its top spot with 2,848 units sold. Following closely in second place was the Indica Relief RSO Syringe (0.5g), also from the Concentrates category. The third spot was reclaimed by the CBD/THC 1:5 Rest Tincture (20mg CBD, 100mg THC, 30ml) from the Tincture & Sublingual category, after dropping to fourth place in October. The CBD/THC 1:1 Relief Tincture (50mg CBD, 50mg THC, 30ml) from the same category slipped to fourth place. A newcomer to the top five was the CBD/THC 1:1 Relief Capsules 20-Pack (50mg CBD, 50mg THC) from the Capsules category, securing the fifth spot.